XEDAR Antibody

Contact us
ProSci
Product Code: PSI-3855
Product Group: Primary Antibodies
Supplier: ProSci
CodeSizePrice
PSI-3855-0.02mg0.02mg£150.00
Quantity:
PSI-3855-0.1mg0.1mg£449.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunohistochemistry (IHC)
  • Western Blot (WB)

Images

1 / 2
Western blot analysis of XEDAR in 293 cell lysate with XEDAR antibody at (A) 0.5, (B) 1 and (C) 2 μg/mL.
2 / 2
Immunohistochemistry of XEDAR in human skin tissue with XEDAR antibody at 10 μg/mL.
❮❯

Western blot analysis of XEDAR in 293 cell lysate with XEDAR antibody at (A) 0.5, (B) 1 and (C) 2 μg/mL.
Immunohistochemistry of XEDAR in human skin tissue with XEDAR antibody at 10 μg/mL.

Documents

Further Information

Additional Names:
XEDAR Antibody: XEDAR, EDAA2R, EDA-A2R, TNFRSF27, XEDAR, UNQ2448/PRO5727/PRO34080, Tumor necrosis factor receptor superfamily member 27, X-linked ectodysplasin-A2 receptor, EDA-A2 receptor
Application Note:
XEDAR antibody can be used for the detection of XEDAR by Western blot at 0.5 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 10 μg/mL.

Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Background:
XEDAR Antibody: X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2). Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain. Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF-κB and JNK pathways. Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis. The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment.
Background References:
  • Yan M, Wang LC, Hymowitz SG, et al. Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science 2000; 290:523-7.
  • Sinha SK, Zachariah S, Quinones HI, et al. Role of TRAF3 and -6 in the activation of the NF-κB and JNK pathways by X-linked ectodermal dysplasia receptor. J. Biol. Chem. 2002; 277:44953-61.
  • Sinha SK and Chaudhary PM. Induction of apoptosis by X-linked ectodermal dysplasia receptor via a caspase 8-dependent mechanism. J. Biol. Chem. 2004; 41873-81.
Buffer:
XEDAR Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
XEDAR antibody was raised against recombinant human XEDAR.
NCBI Gene ID #:
60401
NCBI Official Name:
ectodysplasin A2 receptor
NCBI Official Symbol:
EDA2R
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
AAQ89953
Protein GI Number:
37222208
Purification:
XEDAR Antibody is affinity chromatography purified via peptide column.
Research Area:
Signal Transduction
Swissprot #:
Q9HAV5
User NOte:
Optimal dilutions for each application to be determined by the researcher.